Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 3, 2014, Pages 495-501

  Ploen, Robert ^a   Sun, Li ^a   Zhou, Wei ^a   Heitmeier, Stefan ^b   Zorn, Markus ^a   Jenetzky, Ekkehart ^c   Veltkamp, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BAYER PHARMA AG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

animal models; antithrombotics; blood brain barrier; brain ischemia; intracerebral hemorrhage; thrombolysis

Indexed keywords

ALTEPLASE; EVANS BLUE; HEMOGLOBIN; RIVAROXABAN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; EXPERIMENTAL STROKE; INTERNATIONAL NORMALIZED RATIO; MACROSCOPIC HEMORRHAGE SCORE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SPECTROFLUOROMETRY; SPECTROPHOTOMETRY; THROMBOEMBOLISM; VALIDITY;

ANIMALS; ANTICOAGULANTS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; RATS; RATS, WISTAR; STROKE; THIOPHENES; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 84896720180     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.226     Document Type: Article

References (42)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
3. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
4. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012; 11: 1066-1081.
5. Steiner T, Bo?hm M, Dichgans M, Diener H, Ell C, Endres M et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.
6. Diener H, Foerch C, Riess H, Ro? ther J, Schroth G, Weber R. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving antithrombotic treatment. Lancet Neurol 2013; 12: 677-688.
7. Adams HP, del Zoppo GJ, Alberts MJ, Bhatt DL, Brass L, Furlan A et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: e478-e534.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Da?valos A, Guidetti D et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
9. Lees KR, Bluhmki E, Kummer R, von, Brott TG, Toni D, Grotta JC et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
10. Pfeilschifter W, Spitzer D, Pfeilschifter J, Steinmetz H, Foerch C, Borlongan CV. Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC. PLoS ONE 2011; 6: e26087.
11. Sun L, Zhou W, Ploen R, Heiland S, Zorn M, Veltkamp R. Rapid reversal of anticoagulation prevents excessive secondary hemorrhage after thrombolysis in a thromboembolic model in rats. Stroke 2011; 42: 3524-3529.
12. Ruecker M, Matosevic B, Willeit P, Kirchmayr M, Zangerle A, Knoflach M et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 2012; 79: 31-38.
13. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. J Am Med Ass 2012; 307: 2600-2608.
14. Rizos T, Horstmann S, Jenetzky E, Spindler M, Gumbinger C, Mo? hlenbruch M et al. Oral anticoagulants - a frequent challenge for the emergency management of acute ischemic stroke. Cerebrovasc Dis 2012; 34: 411-418.
15. Dempfle C, Hennerici MG. Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs. Cerebrovasc Dis 2011; 32: 616-619.
16. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-An oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
17. Zhou W, Zorn M, Nawroth P, Bu? tehorn U, Perzborn E, Heitmeier S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
18. Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-Associated intracerebral hemorrhage. Stroke 2011; 42: 191-195.
19. Rizos T, Herweh C, Jenetzky E, Lichy C, Ringleb PA, Hacke W et al. Point-ofcare international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009; 40: 3547-3551.
20. Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C et al. Laboratory assessment of rivaroxaban: a review. Thromb J 2013; 11: 11.
21. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
22. Sun L, Zhou W, Ploen R, Zorn M, Veltkamp R. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 2013; 110: 153-161.
23. Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK et al. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke 2002; 33: 578-585.
24. Sun L, Zhou W, Heiland S, Marti HH, Veltkamp R. A translationally relevant thromboembolic stroke model for the study of secondary hemorrhage after thrombolysis in rats. Brain Res 2011; 1368: 346-354.
25. Choudhri TF, Hoh BL, Solomon RA, Connolly ES, Pinsky DJ. Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke 1997; 28: 2296-2302.
26. Uyama O, Okamura N, Yanase M, Narita M, Kawabata K, Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J Cereb Blood Flow Metab 1988; 8: 282-284.
27. Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996; 739: 88-96.
28. Veltkamp R, Siebing DA, Sun L, Heiland S, Bieber K, Marti HH et al. Hyperbaric oxygen reduces blood-brain barrier damage and edema after transient focal cerebral ischemia. Stroke 2005; 36: 1679-1683.
29. Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff- Last E et al. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol 2012; 71: 624-633.
30. Bohmann F, Mirceska A, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C et al. No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS ONE 2012; 7: e40804.
31. Gliem M, Hermsen D, van Rooijen N, Hartung H, Jander S. Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice. Stroke 2012; 43: 3352-3357.
32. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deepvein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
33. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
34. Harenberg J, Marx S, Weiss C, Kra?mer R, Samama MM, Schulman S. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10: 1433-1436.
35. Wang X, Tsuji K, Lee S, Ning M, Furie KL, Buchan AM et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004; 35: 2726-2730.
36. McLean K, Schirm S, Johns A, Morser J, Light DR. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb Res 2001; 103: 281-297.
37. Ossovskaya VS, Bunnett NW. Protease-Activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
38. Bukowska A, Zacharias I, Weinert S, Skopp K, Hartmann C, Huth C et al. Coagulation factor Xa induces an inflammatory signalling by activation of proteaseactivated receptors in human atrial tissue. Eur J Pharmacol 2013; 718: 114-123.
39. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci 2011; 34: 198-209.
40. Sen P, Gopalakrishnan R, Kothari H, Keshava S, Clark CA, Esmon CT et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011; 117: 3199-3208.
41. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-1285.
42. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.